Are psychiatric disorders associated with worse asthma control and quality of life in asthma patients?  by Lavoie, Kim L. et al.
ARTICLE IN PRESSRespiratory Medicine (2005) 99, 1249–1257KEYWORD
Psychiatric
disorders;
Asthma co
Quality of
Depression
Anxiety
0954-6111/$ - s
doi:10.1016/j.r
Correspondi
Montreal, Que.
E-mail addrAre psychiatric disorders associated with
worse asthma control and quality of life in
asthma patients?
Kim L. Lavoiea,b,c,, Andre´ Cartiera, Manon Labrecquea,
Simon L. Bacona,b,d, Catherine Lemie`rea, Jean-Luc Maloa,
Guillaume Lacostea, Silvana Baronea,b, Pierre Verriere, Blaine Dittoa,baResearch Center, Division of Chest Medicine, Hoˆpital du Sacre´-Cœur de Montre´al, J-3190,
5400 Gouin West, Montreal, Que., Canada H4J 1C5
bDepartment of Psychology, McGill University, 1205 Dr. Penfield Ave. Montreal, Que., Canada H3A 1B1
cDepartment of Psychology, University of Quebec at Montreal (UQAM), P.O. Box 8888, Succ. Centre-Ville,
Montreal, Que., Canada H3C 3P8
dDepartment of Nuclear Medicine, Montreal Heart Institute, 5000 Belanger East, Montreal, Que.,
Canada H1 T 1C8
eDepartment of Psychosomatic Medicine, Hoˆpital du Sacre´-Cœur de Montre´al, 5400 Gouin West,
Montreal, Que., Canada H4J 1C5
Received 20 December 2004S
ntrol;
life;
;
ee front matter & 2005
med.2005.03.003
ng author. Research Ce
, Canada H4J 1C5. Tel.
ess: kimlavoie@crhsc.uSummary
Background: Achieving good asthma control has become the major goal of asthma
treatment. Studies have reported a high rate of psychiatric disorders among asthma
patients, though the impact of these disorders on asthma control and quality of life
remains unexplored. This study evaluated the prevalence of psychiatric disorders in
406 adult asthma patients, and associations between psychiatric status, levels of
asthma control, and asthma-related quality of life.
Methods: Consecutive asthma patients presenting to the asthma clinic underwent a
brief, structured psychiatric interview, completed the Asthma Control Questionnaire
(ACQ) and Asthma Quality of Life Questionnaire (AQLQ), and reported the frequency
of bronchodilator use in the past week. All patients underwent standard pulmonary
function testing.
Results: A total of 34% ðn ¼ 136Þ of patients had one or more psychiatric diagnosis,
including major depression (15%), minor depression (5%), dysthymia (4%), panicElsevier Ltd. All rights reserved.
nter, Division of Chest Medicine, Hoˆpital du Sacre´-Cœur de Montre´al, J-3190, 5400 Gouin West,
: +514 338 2222 3364; fax: +514 338 3123.
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K.L. Lavoie et al.1250disorder (12%), generalized anxiety disorder (5%), and social phobia (4%). Though
there were no differences in pulmonary function, patients with versus without
psychiatric disorders had worse ACQ and AQLQ scores and reported greater
bronchodilator use, independent age, sex and asthma severity.
Conclusions: Results suggest that psychiatric disorders are prevalent among
asthmatics and are associated with worse asthma control and quality of life.
Physicians should be aware of the potential risk of poorer asthma control and
functional impairment in this population.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Asthma remains one of the most prevalent chronic
respiratory disorders, affecting 100–150 million
people worldwide.1,2 The cost of caring for asthma
has been calculated by the World Health Organiza-
tion to exceed that of AIDS/HIV and tuberculosis
combined.1 These figures highlight the scope of the
burden associated with this disease and its impact
on quality of life. The high burden of asthma
appears to be related to poor asthma control,
which is associated with more frequent asthma
symptomatology (dyspnea, wheezing, nocturnal
waking symptoms), bronchodilator use, functional
impairment (absenteeism, participation in social
and physical activities), and worse pulmonary
function.3,4 Given that asthma can be well con-
trolled for the majority of patients,5,6 identifying
those patients who may be at greater risk for poorly
controlled asthma and worse quality of life there-
fore represents an important goal for clinical
research.
Several psychosocial and emotional factors have
been found to be associated with poor asthma
control and worse asthma-related quality of life,
including anxiety, depression, and inappropriate
(e.g., avoidant) coping skills.7–12 However, rela-
tively few studies have evaluated the impact of
chronic psychopathology, i.e., psychiatric disor-
ders, on levels of asthma control and quality of life.
Interestingly, rates of certain psychiatric disorders
(e.g., panic disorder, major depression) among
asthmatics have been reported to be at least
double those observed in the general popula-
tion,9,12–16 suggesting a need to better understand
the impact of such disorders on levels of asthma
control and related outcomes.
The purpose of the present study was twofold:
(1) to evaluate the prevalence of psychiatric
disorders in a large group of adult asthma out-
patients and (2) to evaluate associations between
psychiatric disorders and levels of asthma control
and asthma-related quality of life. It was hypothe-
sized that asthmatics with comorbid psychiatric
disorders would have worse asthma control andasthma-related quality of life relative to asth-
matics without psychiatric disorders, and that
these associations would be independent of age,
sex, and asthma severity.Materials and methods
Study subjects
Participants were recruited from consecutive adult
patients presenting to the asthma clinic of Hoˆpital
du Sacre´-Coeur de Montre´al from June 2003 to
March 2004. Patients were eligible if they had a
primary clinical diagnosis of asthma, were at least
18 years of age or older, and were fluent in either
English or French. A total of 935 patients presented
to the asthma clinic, of which 825 were contacted
to participate (88%). A total of 385 were excluded
(n ¼ 126 due to existence of comorbid disease
(e.g., chronic obstructive pulmonary disease) that
conferred greater risk for morbidity than asthma;
n ¼ 127 due to
’ ’
new’’ or unconfirmed asthma or
occupational asthma; n ¼ 103 were under the age
of 18; n ¼ 22 due to language criteria (did not
speak English or French fluently enough to reliably
complete the assessments); n ¼ 7 due to missing
data), which yielded a total sample of 440 eligible
patients. Only 34 patients declined to participate,
which resulted in a final sample of 406 patients
(92% participation rate). This project was approved
by the Ethics Committee of Hoˆpital du Sacre´-Cœur
de Montre´al.Study design
Patients were screened on the day of their asthma
clinic visit to verify eligibility. Participants under-
went a demographic and medical history interview,
including asking patients to report the frequency
of bronchodilator use in the past week, followed
by a brief, structured psychiatric interview (Pri-
mary Care Evaluation for Mental Disorders, PRIME-
MD) administered by a trained clinical research
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assessing asthma control (Asthma Control Ques-
tionnaire—ACQ) and quality of life (Asthma Quality
of Life Questionnaire—AQLQ) and underwent stan-
dard spirometry to measure pulmonary function.
Asthma diagnoses were confirmed by chart evi-
dence of a 20% fall in FEV1 after methacholine
challenge and/or bronchodilator reversibility in
FEV1 of X20% predicted.
17 Asthma severity was
determined according to 1997 NHLBI guidelines18
that categorize asthma severity into four cate-
gories (mild intermittent, mild persistent, moder-
ate persistent, and severe persistent) based on
clinical symptoms, medication usage, and pulmon-
ary function. Medical history, including medication
status and dosage was self-reported and verified by
chart review.Measures
Psychiatric assessment
Participants underwent a brief, structured psychia-
tric interview using the Primary Care Evaluation of
Mental Disorders (PRIME-MD),19 which is a well-
validated screening instrument designed to detect
the most common Diagnostic and Statistical Manual
of Mental Disorders—4th Edition (DSM-IV)20 dis-
orders in primary care settings. It uses diagnostic
algorithms to generate diagnoses based on DSM-IV
criteria that have been shown to be of comparable
reliability as longer structured interviews.19,21 The
PRIME-MD takes between 10 and 20min to admin-
ister and score, and consists of a 27-item patient
self-report questionnaire, followed by a 12 page
structured interview that is used to follow-up
patient responses. It has been used successfully in
previous studies assessing the prevalence of psy-
chiatric disorders in asthma patients.9,15Asthma control and quality of life assessment
To assess asthma control, participants completed
the ACQ,22 reported the frequency (number of
times in the last week) of bronchodilator use, and
underwent standard spirometry to assess pulmon-
ary function (forced expiratory volume in one
second, FEV1). The ACQ evaluates asthma control
according to standard criteria specified by interna-
tional guidelines.6 Respondents are asked to recall
their symptoms, activity limitations, and broncho-
dilator use in the last week. One additional
question assessing spirometry results (FEV1, %
Pred.) is completed by the research assistant. The
ACQ contains 7 items rated on a 7-point scale
(0 ¼ good control, 6 ¼ poor control). To assess
asthma quality of life, participants completed theAQLQ.23 The AQLQ evaluates asthma quality of life
across four domains: activity limitation, symptoms,
emotional distress, and environmental stimuli. It
contains 32 items rated on a 7-point scale
(1 ¼ maximal impairment, 7 ¼ no impairment).
Both the ACQ and AQLQ have demonstrated very
good measurement properties, including high intra-
class correlation coefficients between 0.90 and
0.95 and good construct, cross-sectional and long-
itudinal validity,22–25 and have been validated in
Quebec French.26
Pulmonary function testing
Rescue medication was withheld for at least 4 h
before pulmonary function tests. FEV1 and forced
vital capacity (FVC) were assessed before adminis-
tration of 200 mg salbutamol using a metered-dose
inhaler or 500 mg terbutaline using a Turbuhalers.
Predicted values of FEV1 and FVC were calculated
from reference values for patients less than27 and
greater28 than 70 years, respectively, yielding %
predicted FEV1 and % predicted FEV1/FVC.
Analyses
Group differences in categorical variables were
examined using Pearson’s w2 test statistics. Group
differences in continuous variables were examined
using t-tests. All tests were two-sided and signifi-
cance was set at 0.05. General Linear Models
controlling for sex, age, smoking status and asthma
severity were used to compare individual item,
subscale, and total scores on the ACQ and AQLQ
questionnaire, as well as frequency of bronchodi-
lator use in the last week. Data analysis was
performed using SAS v8.2 (SAS Institute, Cary NC).Results
Sample characteristics
A total of 406 asthma outpatients participated in
the present study. Participants were 62% female
and had a mean age of 50 (714.5) years.
Prevalence of psychiatric disorders
A total of 34% of patients met diagnostic criteria for
one or more psychiatric disorder (Table 1). A total
of 25% of patients met diagnostic criteria for one or
more anxiety disorder, the most common of which
was panic disorder at 12%. A total of 20% of patients
met diagnostic criteria for one or more mood
disorders, the most common of which was major
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36% of patients reported a lifetime history of panic
attacks. Despite a high rate of current psychiatric
morbidity in this sample, only 13% ðn ¼ 19=136Þ of
psychiatric patients reported currently being under
the care of a mental health professional.
Sociodemographic and patient
characteristics
Sociodemographic and patient characteristics pre-
sented as a function of psychiatric group (asth-
matics with and without one or more cormorbidTable 1 Prevalence of DSM-IV psychiatric dis-
orders.
N ¼ 406 % ðnÞ
Any psychiatric disorder 34 (136)
Anxiety disorders 25 (103)
Panic disorder 12 (49)
Generalized anxiety disorder 5 (21)
Social anxiety disorder 4 (18)
Other anxiety disorder 11 (45)
Mood disorders 20 (81)
Major depressive disorder 15 (59)
Minor depressive disorder 5 (22)
Dysthymia 4 (18)
Bipolar disorder 1 (1)
History of panic attacks 36 (146)
Psychiatric patients under care of
mental health professional
13 (19)
Includes psychologist or psychiatrist.
Table 2 Sociodemographic and patient characteristics a
% ðnÞ N
n
Age (yr) 5
Sex (female) 5
Ethnicity (Caucasian vs. all other ethnic groups) 9
Married/living together 7
Years of education 1
Employed 6
Smoking status
Never smoked 5
Past smoker 4
Current smoker 9
Pack-years y 1
Values are M7SD; results are t-tests.
yPack-years ¼ average number of packs (20 cigarettes) smokedpsychiatric disorder) are presented in Table 2.
There were significantly more women and current
smokers in the psychiatric group and significantly
fewer patients who had never smoked in the
psychiatric group. There were no other significant
differences between groups.Medical characteristics and medications
Medical characteristics and asthma medications
presented as a function of psychiatric group are
presented in Table 3. There were significantly more
patients taking benzodiazepines and antidepres-
sants in the psychiatric group relative to the non-
psychiatric group. There were no other significant
group differences in medical characteristics, asth-
ma severity classification, or the proportion of
patients taking various asthma medications.Asthma control and quality of life
Asthma control and quality of life data presented
as a function of psychiatric group are shown in
Table 4. There were no differences between groups
in pre-bronchodilator FEV1, measured in liters or as
a percentage of predicted values (% predicted); nor
were there any differences in FEV1/FVC (% pre-
dicted). However, asthmatics with cormorbid psy-
chiatric disorders reported significantly more
bronchodilator use in the last week, independent
of age, sex and smoking status and asthma severity,
compared to non-psychiatric asthmatics. Asth-
matics with comorbid psychiatric disorders
also had significantly higher scores on the ACQ,s a function of psychiatric group.
o-psych Psych w2 P
¼ 270 n ¼ 136
1714.5 48714.5 1.64 0.10
7 (154) 71 (97) 7.82 0.005
2 (248) 96 (130) 1.97 0.16
0 (180) 62 (84) 2.95 0.09
373.7 1374.2 0.78 0.44
3 (160) 54 (74) 2.41 0.12
8.73 0.01
1 (138) 40 (55)
0 (109) 42 (57)
(23) 18 (24)
1720.0 13720.0 0.07 0.48
per day multiplied by the number of years smoked.
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Table 3 Medical characteristics and medications as a function of psychiatric group.
% ðnÞ No-psych Psych w2 P
n ¼ 270 n ¼ 136
Hypertension 26 (71) 20 (27) 2.05 0.15
Diabetes 7 (20) 7 (9) 0.09 0.77
BMI (kg/m2) 2775.0 2876.3 0.10 0.33
Atopic 60 (159) 67 (90) 1.93 0.17
Medications-asthma
Short-acting bronchodilators 95 (259) 95 (130) 0.03 0.87
Long-acting bronchodilators 53 (142) 49 (66) 0.49 0.48
Inhaled corticosteroids (ICS) 73 (197) 78 (106) 1.84 0.28
yICS dose (mg) 500 (0–2500) 500 (0–2000) 0.96 0.34
Oral corticosteroids 12 (31) 12 (16) 0.01 0.92
Anti-leukotrienes 12 (33) 13 (17) 0.01 0.91
Medications-psychotropic
Benzodiazepines 10 (27) 23 (31) 12.3 0.0004
Antidepressants 4 (11) 20 (27) 26.8 0.0001
Asthma severity classification 2.86 0.41
Mild intermittent 1 (3) 0
Mild persistent 12 (29) 8 (10)
Moderate persistent 55 (139) 56 (69)
Severe persistent 32 (81) 36 (45)
Asthma duration (yr) 20.3715 18.4715 1.09 0.28
yMedian (range) flucatisone propionate equivalent, result is a t-test (data available for 222 non-psych and 104 psych
participants).
Value is M7SD; result is a t-test.
Table 4 Pulmonary function, bronchodilator use, and ACQ and AQLQ scores as a function of psychiatric group.
M7SD No-psych Psych F P
n ¼ 270 n ¼ 136
FEV1 (l)
 2.370.88 2.370.80 0.00 0.97
FEV1, % predicted
 76.1720.7 78.1719.1 0.78 0.38
FEV1/FVC, % predicted
 86.3712.5 88.7713.1 3.19 0.08
Bronchodilator use (#times in last week)y 9.471.0 13.771.5 5.14 0.02
ACQ (total)y 1.670.06 2.070.09 11.6 0.0007
Q 1: Nocturnal waking 0.370.09 1.370.12 6.2 0.01
Q 2: Waking symptoms 1.370.09 1.770.13 5.7 0.01
Q 3: Activity limitation 1.170.09 1.870.12 20.6 0.0001
Q 4: Shortness of breath 1.870.09 2.570.13 18.4 0.0001
Q 5: Wheezing 1.670.09 2.070.13 6.2 0.01
Q 6: Bronchodilator use 1.170.09 1.470.11 3.6 0.06
Q 7: % FEV1 2.970.09 2.770.13 2.92 0.08
AQLQ (total)y 5.370.08 4.670.12 25.1 0.0001
Activity limitation 5.170.10 4.470.13 20.2 0.0001
Symptoms 5.370.08 4.670.12 20.6 0.0001
Environmental stimuli 5.070.10 4.370.15 14.7 0.0002
Emotional distress 5.770.08 4.970.13 24.9 0.0001
FEV—forced expiratory volume; FVC—forced vital capacity; ACQ—Asthma Control Questionnaire; AQLQ—Asthma Quality of
Life Questionnaire.
Adjusted values controlling for smoking status, asthma severity; 7SEM.
yMean ACQ and AQLQ total scores, subscale scores and individual items adjusted controlling for sex, age, smoking status, and
asthma severity; 7SEM.
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lative to non-psychiatric asthmatics (Table 4). With
the exception of question 7 (% predicted FEV1) and
a marginally significant trend for question 6
(bronchodilator use), asthmatics with comorbid
psychiatric disorders exhibited significantly higher
scores on each individual item of the ACQ,
indicating that in the last week, asthmatics with
comorbid psychiatric disorders experienced more
nocturnal waking due to asthma; worse asthma
symptoms in the morning; greater limitations in
their daily activities; greater shortness of breath
due to asthma; and greater wheezing relative to
non-psychiatric asthmatics. These findings were
statistically significant even after controlling for
sex, age, smoking status and asthma severity.
Asthmatics with comorbid psychiatric disorders
also had significantly lower scores on the AQLQ,
both for the total scale score and each of the four
subscales (Table 4). Therefore, asthmatics with
comorbid psychiatric disorders reported signifi-
cantly worse asthma quality of life, both in general
and in relation to their symptomatology, being
limited in their daily activities, in response to
environmental stimuli, and in regards to feelings of
emotional distress. These findings were significant
after controlling for sex, age, smoking status and
asthma severity. Moreover, all differences between
the mean total and subscale scores on the AQLQ for
asthmatics with versus without psychiatric disor-
ders were also clinically significant as they all
exceeded 0.5 (range 0.7–0.8), where differences of
X0.5 have been defined previously as clinically
significant for this population.22Discussion
The results of the present study indicate a high rate
(34%) of psychiatric disorders among adult asth-
matics. Consistent with hypotheses, asthmatics
with comorbid psychiatric disorders have worse
asthma control and quality of life, independent of
sex, age, smoking status and asthma severity,
relative to asthmatics without psychiatric disor-
ders. Though objective measures of pulmonary
function were comparable between groups, asth-
matics with psychiatric disorders reported greater
use of short-acting bronchodilators in the last
week, also suggesting poorer asthma control in this
population of asthmatics.
Compared to point prevalence rates in the
general population, rates of both anxiety and mood
disorders were at least double those observed in
the general population (25% and 20% versus 1–13%and 2–9%, respectively 20,29). Moreover, rates of
certain psychiatric disorders, including panic dis-
order and major depressive disorder, were as much
as six times more prevalent among asthmatics
relative to the general population.20,29 These
findings are consistent with previous reports sug-
gesting a high rate of psychiatric disorders,
particularly mood (range 14–41%)9,12,14,15 and
anxiety (range 9–24%)13–15,30 disorders, among
adult asthmatics.
To our knowledge, this is the first study to
indicate a strong and independent association
between psychiatric disorders and worse asthma
control and quality of life. This study is consistent
with the relatively few studies finding associations
between actual psychiatric disorders and asthma
morbidity, including worse asthma control and
adherence to inhaled steroids8and worse quality
of life.9However, the present study strengthens
previous reports by finding associations between
psychiatric disorders and worse asthma control and
quality of life independent of asthma severity. It
also strengthens previous reports by including a
large sample size (over 400) of adult asthmatics
with confirmed asthma. Previous studies assessing
the prevalence of psychiatric disorders either had
small sample sizes (less than 110),8,12–14did not
include assessments of asthma morbidity,13–16 or
failed to measure pulmonary function,8,9,13–16
potentially limiting the generalizability, strength
and clinical relevance of the findings.
The association between psychiatric disorders
and poor asthma control and asthma-related
quality of life could occur through several pathways
including behavioral pathways, such as disorga-
nized self-care and poor health behaviors; cogni-
tive or perceptual pathways, such as biased
symptom reporting; or through the direct physio-
logical effects of depression and anxiety on the
autonomic nervous (ANS) and immune systems
which increase asthma symptomatology.
Previous studies have found consistent relation-
ships between psychiatric disorders, particularly
mood and anxiety disorders, and increased rates of
smoking,31–33 which may complicate asthma man-
agement34,35 and quality of life.36 There is also
evidence showing that asthmatics reporting greater
levels of psychological distress (e.g., anxiety,
depression) misuse medication.8,37 Of course, non-
adherence to asthma medications has been directly
linked to several indices of poor outcome, including
increased use of emergency services38 and near-
fatal asthma attacks.39 Though we did not measure
medication adherence in the current study, future
research should include measures of treatment
adherence to help elucidate the mechanisms of
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tric disorders.
Findings of worse asthma control and quality of
life in asthma patients with psychiatric disorders
could also have occurred through cognitive or
perceptual pathways, whereby psychiatric patients
may have been more likely to over-report the
frequency and/or severity of asthma symptoms as a
result of their negative mood states. Previous
studies have shown that psychiatric patients may
be
’ ’
hyper-sensitive’’ to changes in bodily sensa-
tions, which may contribute to distorted symptom
perceptions in this population.40,41 However, there
is evidence from asthma studies showing that
overperception of asthma symptoms may occur
independently of emotional or psychiatric fac-
tors.42,43 The fact that physicians rely so heavily
upon patient self-reports of their symptoms sug-
gests that the potential influence of negative mood
states on symptom perception should be taken into
account when evaluating levels of asthma control
and quality of life in patients with suspected or
known psychiatric morbidity.
Poorer asthma control in asthmatics with psy-
chiatric disorders could also occur through direct
effects of chronic psychological stress on the ANS
and immune systems. Chronic psychological stress
(as is the case in patients with psychiatric
disorders) has been linked to both ANS dysregula-
tion and reduced immunocompetence in asth-
matics. Several studies have reported associations
between certain emotional states (e.g., depres-
sion, hopelessness) and increased cholinergically
mediated airway reactivity in asthmatics.44–46 It
has also been suggested that asthmatics who
experience chronic psychological stress may be in
a chronic proinflammatory state. Evidence for this
association comes from two studies which found
that examination stress was associated with in-
creased production of proinflammatory superoxides
and increased cytokine production by lymphocytes
among asthmatics.47,48 Although these studies
suggest plausible mechanisms by which chronic
psychopathology and psychological stress may
affect asthma control, this research is still in its
infancy and future research is needed to fully
elucidate the nature and significance of these
associations.
The present study may be limited by the fact that
the sample was drawn from a tertiary asthma
clinic; therefore, findings may not generalize to
asthmatics treated in primary care. The present
study may also be limited by the fact that most
measures of asthma control and quality of life were
based on self-report assessments, which may be
subject to recall bias. However, the instrumentsused in the present study (ACQ and AQLQ) have
both been shown to be valid evaluative and
discriminative tools with excellent measurement
properties.22–25 Moreover, a recent study by Juniper
et al.24 found that the self-report questionnaire
version of the ACQ demonstrated superior relia-
bility and discriminative validity than did a daily
diary version of the scale, which was thought to be
less subject to recall bias. Similarly, the AQLQ has
shown strong correlations between the four sub-
scales of the questionnaire and several relevant
asthma outcomes, including asthma severity, asth-
ma control, medication requirements, and overall
quality of life.23 The AQLQ has also been argued to
measure the component of asthma
’ ’
most impor-
tant to patients,’’23 suggesting that self-report
instruments may provide potentially valuable in-
formation not always captured by traditional
(medical) assessments.
Finally, this study may be limited by the cross-
sectional nature of the design. We therefore cannot
conclude that psychiatric disorders among asth-
matics cause worse asthma control and quality of
life, because the reverse may be equally plausible:
that poor asthma control and quality of life leads to
greater psychiatric morbidity. As such, prospective
studies are needed to better delineate these
relationships. It may also be beneficial to conduct
intervention trials designed to treat comorbid
psychiatric disorders among asthmatics, and eval-
uate the efficacy and effectiveness of such inter-
ventions on both psychiatric and asthma outcomes.
To our knowledge, there have been no controlled
treatment outcome studies of empirically validated
interventions (i.e., pharmacotherapy and/or cog-
nitive-behavioral therapy) in patients with both
asthma and psychiatric disorders. It is noteworthy
that the NHLBI guidelines for asthma treatment
recommended referral of asthmatics to mental
health professionals when stress appears to inter-
fere with medical management of asthma.18
Though more patients with psychiatric disorders
were taking psychotropic medications, alarmingly
few (13%) reported being under the care of a
mental health professional. This suggests that
greater efforts should be made to improve referral
and follow-up of these patients to appropriate
treatment providers.
In conclusion, the results of this study highlight
the high prevalence of psychiatric disorders among
adult outpatient asthmatics, and the range of
increased morbidity that may be associated with
it. These findings also suggest that physicians may
want to consider the potential impact of negative
mood states when assessing levels of asthma
control and implementing treatment strategies. It
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with increased symptom perception and/or symp-
tom reporting, which may be falsely interpreted as
poor asthma control by both patients and physi-
cians. Nonetheless, physicians still rely heavily
upon patient reports of symptoms when making
treatment decisions, and should be aware of the
heightened symptomatology, greater functional
impairment, and poorer asthma control in this
population.Acknowledgement
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